GE Roytberg^1,2, OO Sharkhun¹*, SI Kot² NV Kondratova² and JV Dorosh¹

¹Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia
²JSC “Medicina”, Moscow, Russia

*Corresponding Author: GE Roytberg, Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation and JSC “Medicina”, Moscow, Russia.

Received: June 23, 2023; Published: October 11, 2023

Abstract

The relevance of developing effective methods for the treatment of neuroendocrine tumors is associated with an increase in the incidence of this type of cancer worldwide. The article presents a review of the literature on the accumulated international experience in peptide receptor radionuclide therapy in neuroendocrine tumors and meningiomas. International practical recommendations on the rational selection of patients for therapy with ¹⁷⁷Lu-DOTATATE are outlined, taking into account the principles of personalized medicine, indications and contraindications for this type of treatment. Considering that the Russian Federation is the largest country in terms of the number of registered patients with neuroendocrine tumors, the introduction of this method of treatment as a second- and third-line therapy will allow such patients to receive an additional effective treatment option, which will increase the time without progression in these patients and will significantly improve their quality of life.

 Keywords: Neuroendocrine Tumors (NETs); Radionuclide Therapy; Oncologist

References

1. MB Dolgushin and IS Stilidi. “PET/CT in practical oncology. Neuroendocrine tumors”. Vidar, (2021): 552.
2. Begum N., et al. “Neuroendocrine Tumours of the GI Tract — Data from the German NET Registry”. Zentralbl Chir3 (2014): 276-283.
3. Yao JC., et al. “One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States”. Journal of Clinical Oncology18 (2008): 3063-3072.
4. Babichev K N., et al. “Fourth ventricle meningiomas. A case report and literature review”. Zhurnal Voprosy Neirokhirurgii Imeni N. N. Burdenko 83.3 (2019): 77-86.
5. Friedlander RM., et al. “Management of meningiomas of the cavernous sinus: conservative surgery and adjuvant therapy”. Clinical Neurosurgery 45 (1990): 279-282.
6. Stafford S L., et al. “Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988“. Mayo Clinic Proceedings10 (1998): 936-942.

       7.    Reubi JC., et al. “Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system". Cancer Research 47.21 (1987):               5758-5764.

8. Krenning E P., et al. “Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin". Lancet 8632 (1989): 242-244.
9. Bombardieri E., et al. “Oncology Committee of the EANM. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging“. European Journal of Nuclear Medicine and Molecular Imaging7 (2010): 1441-1448.
10. Janssen I., et al. “Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma”. Clinical Cancer Reserach17 (2015): 3888-3895.
11. Fallahi B., et al. “Diagnostic efficiency of ⁶⁸Ga-DOTATATE PET/CT as compared to ^99mTc-Octreotide SPECT/CT and conventional morphologic modalities in neuroendocrine tumors”. Asia Oceania Journal of Nuclear Medicine and Biology 2 (2019): 129-140.
12. Briganti V., et al. “99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases)”. Current Radiopharmaceuticals 13 (2020): 166-176.
13. Кwekkeboom D J and Krenning EP. "Somatostatin receptor imaging". Seminars in Nuclear Medicine2 (2002): 84-91.
14. Dutour A., et al. “Expression of somatostatin receptor subtypes in human brain tumors”. International Journal of Cancer5 (1998): 620-627.
15. Schulz S., et al. “Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype SST2A". Clinical Cancer Research5 (2000): 1865-1874.
16. Soto-Montenegro ML., et al. “Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice”. PLoS One11 (2014): e111624.
17. Afshar-Oromieh A., et al. “Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI”. European Journal of Nuclear Medicine and Molecular Imaging 39.9 (2012): 1409-14
18. Rachinger W., et al. “Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue”. Journal of Nuclear Medicine 56.3 (2015): 347-3
19. Nyuyki F., et al. “Potential impact of (68)Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas”. European Journal of Nuclear Medicine and Molecular Imaging 2 (2010): 310-318.
20. Graf R., et al. “Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy”. International Journal of Radiation Oncology - Biology - Physics 1 (2013): 68-73.
21. Gehler B., et al. “[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning”. Radiation Oncology4 (2009): 56.
22. Combs SE., et al. “Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET”. Acta Oncology 3 (2013): 514-520.
23. Levine R and Krenning E "Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine”. Journal of Nuclear Medicine 58 (2017): 3S-9S.
24. Valkema R., et al. “Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA (0),Tyr (3)-octreotide and (177)Lu-DOTA (0), Tyr (3)-octreotate”. Journal of Nuclear Medicine 46 (2005): 83S-91S.
25. Strosberg J., et al. “NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors”. The New England Journal of Medicine2 (2017): 125-135.
26. Strosberg JR., et al. “¹⁷⁷Lu-Dotatate plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial”. Lancet Oncology12 (2021): 1752-1763.
27. Kwekkeboom D J., et al. “Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3] octreotate: toxicity, efficacy, and survival”. Journal of Clinical Oncology13 (2008): 2124-2130.
28. https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_de.pdf
29. https://pubmed.ncbi.nlm.nih.gov/32272208/
30. Kwekkeboom D J and Krenning EP. "Somatostatin receptor imaging”. Seminars in Nuclear Medicine2 (2002): 84-91.
31. Bodei L., et al. “The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours”. European Journal of Nuclear Medicine and Molecular Imaging 40.5 (2013): 800-8

Citation

Citation: GE Roytberg., et al. “¹⁷⁷Lu-DOTATATE Radionuclide Therapy: Current Status and Trends”.Acta Scientific Medical Sciences 7.11 (2023): 86-92.

Copyright

Copyright: © 2023 GE Roytberg., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.